Cure8 news brief
Long-term results matter because they report whether an IL‑23 inhibitor (Omvoh) maintained clinical and endoscopic improvements through two years for people with moderate-to-severe Crohn’s disease, including some with prior biologic failure.
That’s relevant for treatment planning and expectations about durability and safety of a newer biologic.
Adults with moderate-to-severe Crohn’s disease, especially those considering or currently on IL‑23 therapies or with prior biologic failure; IBD clinicians and researchers tracking new biologic data.
This is a company report of long-term extension results for Omvoh in Crohn’s disease (patients previously in VIVID-1 continued into VIVID-2). The release gives percentages for maintained or gained clinical and endoscopic outcomes at two years and notes serious adverse events and discontinuations during year two.
It does not provide full study tables, detailed denominators, statistical testing, or peer-reviewed publication text in this item.
If you want details: look for the Crohn’s & Colitis Congress presentation or a full company clinical study report/publication to see patient numbers, exact definitions, comprehensive safety data, and analysis methods (the article references both observed-case and modified non-responder imputation analyses).
This Business Insider markets article summarizes a company announcement; the full data are being presented at a professional congress. Company press summaries are useful for initial signals but should be confirmed by the full congress presentation, peer‑reviewed publication, or independent analyses before changing care decisions.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
These are multi‑year clinical results for a newly approved IL‑23p19 inhibitor (mirikizumab) showing sustained clinical and endoscopic benefit for many patients with moderate‑to‑severe Crohn’s disease, including some who...
Longer-term data help patients and clinicians understand whether an initial response to a new biologic (mirikizumab) is likely to last and whether safety findings remain acceptable over two years.
Early “top-down” infliximab plus an immunomodulator was linked to much lower 5-year risk of abdominal surgery, disease progression, and hospitalization versus a step-up approach. This could influence treatment planning...
